A PILOT, PHASE IB FEASIBILITY STUDY OF ARGX-110 IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA (NPC).

Prof. Dr. Sylvie Rottey – XX May 2017
NPC- Definition

Nasopharyngeal carcinoma (NPC) is a cancer that occurs in the nasopharynx, which is located behind the nose and above the back of the throat.
NPC - Epidemiology

- 0.5 – 2 new cases/100 000 people (Europe + VS)
- male > female
- linked with Epstein Barr Virus (EBV) - % pos?
NPC - Treatment

Highly radiosensitive
Highly chemosensitive

=> platinum based chemoRT = golden standard 
   (stage III/IV)

=> platinum based chemotherapy is = golden standard for metastatic disease
NPC - Outcome

For **metastatic NPC**, median survival is only 12–20 months
=> Need for new therapies (e.g. targeted agents)
Adaptive Immune response
ARGX-110: monoclonal anti-CD70 antibody op de vorige slide in de tekening bij te zetten ipv deze slide?
anti-CD70 mAb

↓ number of T regs

direct cytotoxic effect
Inclusion criteria:
- ≥ 18 years old
- ECOG ≤ 2
- Adequate bone marrow,
  Adequate liver and renal function

Exclusion criteria:
- CNS involvement
- Major surgery prior to therapy
- Grade 3/4 toxicity from prior therapy
- Active infection
- Childbearing potential/pregnancy/lactation
- Hypersensitivity to recombinant proteins
- Psychiatric/behavioural problems

ARGX-110:
5 mg/kg,
IV,
every three weeks

Primary endpoint:
Safety profile of ARGX-110
Results

– n= eleven patients (nine male, two female) were enrolled in our center since February 2015.
– median age of 47 years (range 23-76)
– All patients were diagnosed with stage III (n=2) or stage IV (n=9) NPC.
Results

– median number of cycles administered was three (range 1 to 18).
– Administration of ARGX-110 was well tolerated. One patient was hospitalized because of infection for which treatment was delayed for three weeks. Two other patients developed an infusion reaction (grade 1-2).
Conclusion

– administration of ARGX-110, 5mg/kg IV every three weeks, is feasible in patients with NPC. Results on PFS and OS overall survival will be reported after completion of the trial.

– the exploration of predictive biomarkers is ongoing (kun je er enkele oplijsten?)
Prof. Dr. Sylvie Rottey
M.D.; PhD

HEYMANS INSTITUTE OF PHARMACOLOGY
DEPARTMENT OF MEDICAL ONCOLOGY
DRUG RESEARCH UNIT GENT

E sylvie.rottey@ugent.be
T +32 9 332 00 00

www.ugent.be